These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39387235)

  • 21. Effect of Gender, Disease Duration and Treatment on Muscle Strength in Myasthenia Gravis.
    Citirak G; Cejvanovic S; Andersen H; Vissing J
    PLoS One; 2016; 11(10):e0164092. PubMed ID: 27741232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
    Vu T; Meisel A; Mantegazza R; Annane D; Katsuno M; Aguzzi R; Enayetallah A; Beasley KN; Rampal N; Howard JF
    Neurol Ther; 2023 Oct; 12(5):1435-1438. PubMed ID: 37351816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eculizumab: A Review in Generalized Myasthenia Gravis.
    Dhillon S
    Drugs; 2018 Mar; 78(3):367-376. PubMed ID: 29435915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
    Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
    Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
    Jiao L; Li H; Guo S
    J Neuroimmunol; 2022 Jan; 362():577767. PubMed ID: 34823117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis.
    Ma Y; Nie X; Zhu G; Qi W; Hao L; Guo X
    CNS Drugs; 2024 Feb; 38(2):93-104. PubMed ID: 38300476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic.
    Kısabay A; Özdemir HN; Gökçay F; Çelebisoy N
    Acta Neurol Belg; 2022 Apr; 122(2):337-344. PubMed ID: 33544334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.
    Howard JF; Vissing J; Gilhus NE; Leite MI; Utsugisawa K; Duda PW; Farzaneh-Far R; Murai H; Wiendl H
    Expert Opin Investig Drugs; 2021 May; 30(5):483-493. PubMed ID: 33792453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
    Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
    Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
    Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
    Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis.
    Antozzi C; Mantegazza R
    Patient Relat Outcome Meas; 2023; 14():305-312. PubMed ID: 37876920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
    Howard JF; Nowak RJ; Wolfe GI; Freimer ML; Vu TH; Hinton JL; Benatar M; Duda PW; MacDougall JE; Farzaneh-Far R; Kaminski HJ; ; Barohn R; Dimachkie M; Pasnoor M; Farmakidis C; Liu T; Colgan S; Benatar MG; Bertorini T; Pillai R; Henegar R; Bromberg M; Gibson S; Janecki T; Freimer M; Elsheikh B; Matisak P; Genge A; Guidon A; David W; Habib AA; Mathew V; Mozaffar T; Hinton JL; Hewitt W; Barnett D; Sullivan P; Ho D; Howard JF; Traub RE; Chopra M; Kaminski HJ; Aly R; Bayat E; Abu-Rub M; Khan S; Lange D; Holzberg S; Khatri B; Lindman E; Olapo T; Sershon LM; Lisak RP; Bernitsas E; Jia K; Malik R; Lewis-Collins TD; Nicolle M; Nowak RJ; Sharma A; Roy B; Nye J; Pulley M; Berger A; Shabbir Y; Sachdev A; Patterson K; Siddiqi Z; Sivak M; Bratton J; Small G; Kohli A; Fetter M; Vu T; Lam L; Harvey B; Wolfe GI; Silvestri N; Patrick K; Zakalik K; Duda PW; MacDougall J; Farzaneh-Far R; Pontius A; Hoarty M
    JAMA Neurol; 2020 May; 77(5):582-592. PubMed ID: 32065623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events.
    Zhdanava M; Pesa J; Boonmak P; Cai Q; Pilon D; Choudhry Z; Souayah N
    Curr Med Res Opin; 2024 Jul; 40(7):1145-1153. PubMed ID: 38745448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature.
    Garzón-Orjuela N; van der Werf L; Prieto-Pinto LC; Lasalvia P; Castañeda-Cardona C; Rosselli D
    Intractable Rare Dis Res; 2019 Nov; 8(4):231-238. PubMed ID: 31890449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Childhood myasthenia gravis: clinical features and outcomes.
    Sri-udomkajorn S; Panichai P; Liumsuwan S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S152-7. PubMed ID: 22043769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
    Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
    Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.
    Ruan Z; Tang Y; Gao T; Li C; Guo R; Sun C; Huang X; Li Z; Chang T
    CNS Neurosci Ther; 2024 Jun; 30(6):e14793. PubMed ID: 38894580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different characteristics of nonthymomatous generalized myasthenia gravis with and without oropharyngeal involvement.
    Yu L; Li J; Ma S; Jiang J; Wang T; Gamliel Z; Jing Y; Zhang X; Krasna MJ
    Ann Thorac Surg; 2007 Nov; 84(5):1694-8. PubMed ID: 17954087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
    Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
    J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.